Published in Br J Clin Pharmacol on March 13, 2008
Clinical update for the diagnosis and treatment of Clostridium difficile infection. World J Gastrointest Pharmacol Ther (2014) 0.81
An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med (2005) 18.10
A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med (2005) 16.59
Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet (2005) 12.54
Clostridium difficile colitis. N Engl J Med (1994) 9.31
Clinical practice. Antibiotic-associated diarrhea. N Engl J Med (2002) 7.13
Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis (2005) 4.89
Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis (2005) 4.42
Clostridium difficile--associated diarrhea. Clin Infect Dis (1998) 4.06
Diagnosis and treatment of Clostridium difficile colitis. JAMA (1993) 3.97
Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol (1997) 3.70
Clostridium difficile infection. Annu Rev Med (1998) 3.63
Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001. J Infect Dis (2004) 3.42
Hospitals battling outbreaks of C. difficile. CMAJ (2004) 2.76
Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis (1998) 2.75
Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis (1997) 2.53
New guidelines for potassium replacement in clinical practice: a contemporary review by the National Council on Potassium in Clinical Practice. Arch Intern Med (2000) 2.00
Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother (2002) 2.00
Clostridium difficile infection in hospitals: a brewing storm. CMAJ (2004) 1.74
Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis (2006) 1.59
Clostridium difficile toxin A and its effects on cells. Toxicon (1991) 1.54
Clostridium difficile: a formidable foe. CMAJ (2004) 1.54
The new Clostridium difficile--what does it mean? N Engl J Med (2005) 1.53
Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med (1989) 1.41
Differential cytotoxic effects of toxins A and B isolated from Clostridium difficile. Infect Immun (1984) 1.28
GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother (2001) 1.25
Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? Clin Infect Dis (1997) 1.25
Metronidazole for Clostridium difficile-associated disease: is it okay for Mom? Clin Infect Dis (2005) 1.21
Clostridium difficile colitis and diarrhea. Gastroenterol Clin North Am (1993) 1.19
Treatment of antibiotic-associated colitis with vancomycin. J Antimicrob Chemother (1984) 1.15
Clindamycin, metronidazole, and chloramphenicol. Mayo Clin Proc (1999) 1.15
N-CDAD in Canada: results of the Canadian Nosocomial Infection Surveillance Program 1997 N-CDAD Prevalence Surveillance Project. Can J Infect Dis (2001) 1.10
Incidence and impact of Clostridium difficile infection in the UK, 1993-1996. J Hosp Infect (1998) 0.96
Clostridium difficile-associated diarrhea and colitis. Mayo Clin Proc (2001) 0.95
Epidemiology of Clostridium difficile infection in a large population of hospitalized US military veterans. Dig Dis Sci (2002) 0.92
Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea. Biophys J (2004) 0.89
Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties. Aliment Pharmacol Ther (2006) 0.86
The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol (2007) 4.09
Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis (2006) 1.59
Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for C. difficile infections: 2005-2007. Anaerobe (2009) 1.47
Absorption of colesevelam hydrochloride in healthy volunteers. Ann Pharmacother (2002) 0.93